ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

Polycystic Ovary Syndrome and Menopause

DOI:10.31550/1727-2378-2018-154-10-47-50
Bibliography link: Nadelyaeva Ya.G., Suturina L.V. Polycystic Ovary Syndrome and Menopause. Doctor.Ru. 2018; 10(154): 47–50. DOI: 10.31550/1727-2378-2018-154-10-47-50
Polycystic Ovary Syndrome and Menopause
16 November 09:57

Objective of the Review: To analyze available data on menopause in women with polycystic ovary syndrome (PCOS) and modern approaches to the diagnosis of PCOS in peri- and postmenopausal women.

Key Points: A search of the literature was conducted using the PubMed and EMBASE databases for the period between 1992 and 2018.

The diagnosis of PCOS in peri- and postmenopausal women is based on a history of menstrual dysfunction and hyperandrogenism during reproductive age, and its persistence after menopause. A polycystic ovarian pattern is considered an additional indicator, but its diagnostic value is low because of age-related changes in ovarian morphology. In women experiencing the onset of hyperandrogenism after menopause and in those with significant or worsening hyperandrogenemia, androgen-secreting tumors and ovarian hyperthecosis should be ruled out. Patients with PCOS are at a higher risk for menopausal metabolic syndrome and later cardiovascular complications.

Conclusion: Current guidelines on the diagnosis of PCOS after menopause focus on the assessment of medical history data on menstrual disorders, previously diagnosed hyperandrogenism, and changes in ovarian morphology. The diagnosis and monitoring of hyperandrogenism in postmenopausal women requires modern laboratory methods and age-specific normal values for various ethnic groups. The elevated risk of metabolic and cardiovascular disorders in postmenopausal patients with PCOS necessitates close monitoring and timely treatment of any abnormalities detected.

Ya.G. Nadelyaeva — Scientific Center for Family Health and Human Reproduction, Irkutsk. E-mail: ianadoc@mail.ru

L.V. Suturina — Scientific Center for Family Health and Human Reproduction, Irkutsk. E-mail: Lsuturina@mail.ru

Polycystic Ovary Syndrome and Menopause
16 November 09:57
LITERATURE
  1. Carmina E., Rosato F., Jannì A., Rizzo M., Longo R.A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrino.l Metab. 2006; 91(1): 2–6. DOI: 10.1210/jc.2005-1457
  2. Lizneva D., Suturina L., Walker W., Brakta S., Gavrilova-Jordan L., Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 2016; 106(1): 6–15. DOI: 10.1016/j.fertnstert.2016.05.003
  3. Welt C.K., Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J. Clin. Endocrinol. Metab. 2013; 98(12): 4629–38. DOI: 10.1210/jc.2013-2375
  4. Franks S., Berga S.L. Does PCOS have developmental origins? Fertil. Steril. 2012; 97(1): 2–6. DOI: 10.1016/j.fertnstert.2011.11.029
  5. Brown Z.A., Louwers Y.V., Fong S.L., Valkenburg O., Birnie E., de Jong F.H. et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil. Steril. 2011; 96(5): 1259–65. DOI: 10.1016/j.fertnstert.2011.09.002
  6. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109–50. DOI: 10.3109/13697137.2015.1129166
  7. Zawadzki J., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J., Haseltine F., Haseltine G., eds. Polycystic ovary syndrome. Oxford: Blackwell Scientific; 1992: 377–84.
  8. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19(1): 41–7.
  9. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009; 91(2): 456–88. DOI: 10.1016/j.fertnstert.2008.06.035
  10. Final Report National Institute of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome December 3–5, 2012. https://prevention-archive.od.nih.gov/docs/programs/pcos/FinalReport.pdf (дата обращения — 12.08.2018).
  11. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565–92. DOI: 10.1210/jc.2013-2350
  12. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 2018; 33(9): 1602–18. DOI: 10.1093/humrep/dey256.
  13. Elting M.W., Korsen T.J., Rekers-Mombarg L.T., Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum. Reprod. 2000; 15(1): 24–8.
  14. Elting M.W., Kwee J., Korsen T.J., Rekers-Mombarg L.T., Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil. Steril. 2003; 79(5): 1154–60.
  15. Alsamarai S., Adams J.M., Murphy M.K., Post M.D., Hayden D.L., Hall J.E. et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J. Clin. Endocrinol. Metab. 2009; 94(12): 4961–70. DOI: 10.1210/jc.2009-0839
  16. Pinola P., Piltonen T.T., Puurunen J., Vanky E., Sundstrom-Poromaa I., Stener-Victorin E. et al. Androgen profile through life in women with polycystic ovary syndrome: a Nordic multicenter collaboration study. J. Clin. Endocrinol. Metab. 2015; 100(9): 3400–7. DOI: 10.1210/jc.2015-2123
  17. Rosner W., Auchus R.J., Azziz R., Sluss P.M., Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J. Clin. Endocrinol. Metab. 2007; 92(2): 405–13. DOI: 10.1210/jc.2006-1864
  18. Rosner W., Vesper H.; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society et al. Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 2010; 95(10): 4542–8. DOI: 10.1210/jc.2010-1314
  19. Stanczyk F.Z. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract. Res. Clin. Endocrinol. Metab. 2006; 20(2): 177–91. DOI: 10.1016/j.beem.2006.03.007
  20. Shah D., Bansal S. Polycystic ovaries — beyond menopause. Climacteric. 2014; 17(2): 109–15. DOI: 10.3109/13697137.2013.828687
  21. Gabrielli L., de Almeida Mda C., Aquino E.M. Proposed criteria for the identification of polycystic ovary syndrome following menopause: an ancillary study of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Maturitas. 2015; 81(3): 398–405. DOI: 10.1016/j.maturitas.2015.04.013
  22. Brown Z.A., Louwers Y.V., Fong S.L., Valkenburg O., Birnie E., de Jong F.H. et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil. Steril. 2011; 96(5): 1259–65. DOI: 10.1016/j.fertnstert.2011.09.002
  23. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387–95. DOI: 10.1097/gme.0b013e31824d8f40
  24. Tom S.E., Mishra G.D. A life course approach to reproductive aging. In: Dvornik V., ed. Current topics in menopause. Bentham Science Publishers Ltd.; 2013: 3–19.
  25. Minooee S., Ramezani Tehrani F., Rahmati M., Mansournia M.A., Azizi F. Prediction of age at menopause in women with polycystic ovary syndrome. Climacteric. 2018; 21(1): 29–34. DOI: 10.1080/13697137.2017.1392501
  26. Tehrani F.R., Solaymani-Dodaran M., Hedayati M., Azizi F. Is polycystic ovary syndrome an exception for reproductive aging? Hum. Reprod. 2010; 25(7): 1775–81. DOI: 10.1093/humrep/deq088
  27. Paramsothy P., Harlow S.D., Elliott M.R., Yosef M., Lisabeth L.D., Greendale G.A. et al. Influence of race/ethnicity, body mass index, and proximity of menopause on menstrual cycle patterns in the menopausal transition: the Study of Women's Health Across the Nation. Menopause. 2015; 22(2): 159–65. DOI: 10.1097/GME.0000000000000293
  28. Sun X., Luo M., Ma M., Tang R., Wang Y., Liu G. et al. Ovarian aging: an ongoing prospective community-based cohort study in middle-aged Chinese women. Climacteric. 2018; 21(4): 404–10. DOI: 10.1080/13697137.2018.1458833
  29. Freeman E.W., Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climaсteric. 2007; 10(3): 197–214. DOI: 10.1080/13697130601181486
  30. Schmidt J., Brännström M., Landin-Wilhelmsen K., Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their agematched controls. J. Clin. Endocrinol. Metab. 2011; 96(7): 2178–85. DOI: 10.1210/jc.2010-2959
  31. Krentz A.J., von Mühlen D., Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose effect association with prevalent cardiovascular disease. Menopause. 2007; 14: 284–92. DOI: 10.1097/GME.0b013e31802cc7ab
  32. Lim S.S., Davies M.J., Norman R.J., Moran L.J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update. 2012; 18(6): 618–37. DOI: 10.1093/humupd/dms030
  33. Markopoulos M.C., Rizos D., Valsamakis G., Deligeoroglou E., Grigoriou O., Chrousos G.P. et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J. Clin. Endocrinol. Metab. 2011; 96(3): 623–31. DOI: 10.1210/jc.2010-0130
  34. Puurunen J., Piltonen T., Jaakkola P., Ruokonen A., Morin-Papunen L., Tapanainen J.S. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2009; 94(6): 1973–8. DOI: 10.1210/jc.2008-2583
  35. Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D. et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health — National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 2008; 93(4): 1276–84. DOI: 10.1210/jc.2007-0425
  36. O'Reilly M.W., Taylor A.E., Crabtree N.J., Hughes B.A., Capper F., Crowley R.K. et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J. Clin. Endocrinol. Metab. 2014; 99(3): 1027–36. DOI: 10.1210/jc.2013-3399
  37. Carmina E., Campagna A.M., Lobo R.A. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors. Hum. Reprod. 2013; 28(8): 2245–52. DOI: 10.1093/humrep/det119
  38. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2002; 87(2): 742–6. DOI: 10.1210/jcem.87.2.8199
  39. Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T. et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. 2006; 36(10): 691–7. DOI: 10.1111/j.1365-2362.2006.01712.x
  40. Merz C.N., Shaw L.J., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D. et al. Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J. Womens Health (Larchmt). 2016; 25(9): 875–81. DOI: 10.1089/jwh.2015.5441
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners